Roles of factor Xa beyond coagulation

Wolfram Ruf

Accepted: 13 April 2021 / Published online: 24 April 2021
© The Author(s) 2021

Abstract

Oral anticoagulant therapy has changed by clinical evidence that coagulation factor Xa (FXa) can be safely and effectively targeted for thromboprophylaxis. Because thrombotic and thrombo-inflammatory diseases are frequently caused by excessive activation of the tissue factor (TF) pathway, activation of FX by the TF-FVIIa complex is of central importance for understanding the roles of FXa in thrombosis and hemostasis and functions beyond blood coagulation. Recent data showed that the nascent product FXa associated with TF-FVIIa not only supports hemostatic cofactor VIII activation, but also broadly influences immune reactions in inflammation, cancer, and autoimmunity. These signaling functions of FXa are mediated through protease activated receptor (PAR) cleavage and PAR2 activation occurs in extravascular environments specifically by macrophage synthesized FX. Cell autonomous FXa-PAR2 signaling is a mechanism for tumor-promoting macrophage polarization in the tumor microenvironment and tissue penetrance of oral FXa inhibitors favors the reprogramming of tumor-associated macrophages for non-coagulant therapeutic benefit. It is necessary to decipher the distinct functions of coagulation factors synthesized by the liver for circulation in blood versus those synthesized by extrahepatic immune cells for activity in tissue milieus. This research will lead to a better understanding of the broader roles of FXa as a central regulator of immune and hematopoietic systems.

Keywords  Protease activated receptors  · Coagulation factor Xa  · Tissue factor pathway

Highlights

• FXa has distinct functions as nascent product of TF-FVIIa and in the FVa-FXa prothrombinase complex.
• Release of FXa from TF-FVIIa is linked to complement- and protein disulfide isomerase-dependent allosteric regulation of TF.
• FXa assembled with TF-FVIIa activates FVIII and thereby hemostatic coagulation as well as PAR2 signaling in immunity.
• Regulated synthesis of FX by innate immune cells controls macrophage function in extravascular milieus.

FX is the preferred substrate for the TF initiation complex

The cloning of the coding sequence for the coagulation initiator TF, which serves as the cell surface receptor and allosteric cofactor for FVIIa [1], initially indicated a structure distinct from the plasma coagulation cofactors V and VIII that support FXa and FIXa, respectively. Structure prediction
algorithms subsequently suggested an evolutionary origin of TF as a member of the cytokine receptor family. Mutational and structural studies rapidly confirmed the fold of TF into two fibronectin type III-like domains typical for these immune receptors and elucidated the structure–function relationships of the interaction between TF and FVIIa [2]. Mutagenesis of TF initially identified an exosite in the carboxyl-terminal extracellular domain of TF. This exosite was not involved in binding of FVIIa and was critically important for the activation of FX to FXa, but much less so for the activation of FIX [3]. Modeling of macromolecular FX docking to the TF-FVIIa coagulation initiation complex

provided a view of the extended contacts between the three proteins and the predicted interactions of FX were consistent with extensive prior and model-probing mutagenesis [2].

Macromolecular substrate FX interacts with TF-FVIIa primarily through multiple and distinct exosites remote from the catalytic cleft of FVIIa (Fig. 1). Specifically, the γ-carboxyglutamic acid-rich (Gla) domains of substrate FX and enzyme FVIIa make contacts with each other as well as the carboxyl-terminal domain of TF. The epidermal growth factor (EGF) 1 domains of FX and FVIIa bind through energetically significant contacts to TF but make little contact with each other. Whereas the protease domain of FVIIa interacts with TF to allow for the allosteric activation of protease function [1], the protease domain of FX and the tightly associated EGF-2 domain primarily interact with an allosterically regulated exosite region of the protease domain of FVIIa (Fig. 1). These extended interactions allow for alignment of macromolecular substrate with the active site of FVIIa, into which the flexible activation peptide of FX docks for cleavage. However, the interactive surface of the FX protease domain with FVIIa is largely unaffected by zymogen to enzyme conversion of the nascent product FXa [2]. Thus, FXa can remain associated with TF-FVIIa before being released for the subsequent reactions in the common coagulation pathway.

Despite the detailed elucidation of the structural basis for TF-FVIIa recognition of FX, subsequent studies have shown that cellular and posttranslational mechanisms are crucial determinants for the distinct functions of the TF initiation complex in thrombosis, hemostasis and cell signaling. Monocytes and macrophages express TF on the surface in an inactive or cryptic form that is converted to fully procoagulant TF in the context of inflammation (Fig. 2). This process requires thiol-disulfide exchange and involves protein disulfide isomerase (PDI) that modify the conformation of the TF extracellular domain through chaperone activity of PDI and reshufling of the allosteric disulfide bond exposed in the carboxyl-terminal domain of TF [4]. The TF

---

**Fig. 1** Assembly of FXa with the TF-FVIIa complex and functions of nascent product related to coagulation and cell signaling. FX interacts with an extended interface created by exosites on TF and FVIIa, but does not dock into the activate site of FVIIa (shown in blue). This stable complex assembly allows for cleavage of the activation peptide bond in zymogen FX, but also for tethering of the nascent product FXa which is involved in regulation of TF function by TFPI, the activation of FVIII in the antihemophilic pathway and cell signaling through PARs. Details of the assembly interaction and active sites can be found in reference [2]

**Fig. 2** Regulation of TF-FVIIa complex functions by complement and PDI. The allosteric Cys186-Cys209 control trafficking of TF-FVIIa and FX turnover. In the cryptic state, TF-FVIIa signals through PAR2 in the endosome and regulates cell migration by associating with integrins. Complement activation induces thiol-disulfide exchange involving PDI and in the context of phosphatidylserine (PS) exposure leads to allosteric activation of TF favoring FX turnover and coagulation

---

© Springer
Cys<sup>186</sup>-Cys<sup>209</sup> disulfide can be S-nitrosylated, reduced or converted to mixed disulfides of TF Cys<sup>209</sup> with thioredoxin (Trx) or glutathione [4]. In the presence of PDI, affinity of TF for FVIIa is high and turnover of macromolecular substrate FX is favored [5].

Complement activation is a crucial trigger for thiol-disulfide exchange pathways and involves antibody binding to monocyte receptors and activation of complement factor 3 in the antiphospholipid syndrome [6, 7] or antibody independent pathways in venous thrombosis [8]. Importantly, conversion of TF to a prothrombotic state requires the cell surface translocation of phosphatidylserine (Fig. 2), although the exposure of negatively charged phospholipids in the absence of PDI is not sufficient for TF prothrombotic activity on extracellular vesicles [5]. Phosphatidylserine exposure can be induced by several inflammatory mechanisms, including complement C5b-C7 membrane insertion leading to thrombosis [4], conventional [5] or non-conventional [9] inflammasome activation in sepsis, or thrombin-PAR1/PAR2 signaling leading to acid sphingomyelinase activation for prothrombotic TF generation and inflammation in the antiphospholipid syndrome [6, 7].

### Function of FXa assembled with the TF-FVIIa complex

The prothrombotic and hemostatic functions of FXa after release from the TF-FVIIa complex and assembly with the plasma coagulation cofactor Va are well characterized, but FXa fulfills distinct roles while associated as a nascent product with TF-FVIIa. FXa can elicit such immediate proteolytic roles because the active site of FXa is not in direct contact with TF-FVIIa and therefore is available to recognize substrates and inhibitors (Fig. 1). The interaction of the second Kunitz-type protease inhibitory domain of TF pathway inhibitor (TFPI) with the active site of FXa is a crucial step required for efficient inhibition of the TF-FVIIa complex by TFPI Kunitz domain 1. This inhibitory complex formation is essential for controlling the activity of TF in coagulation as well as cell signaling [10]. Although imaging has shown that the TF-FVIIa-FXa-TFPI complex forms and persists on monocyte cell surfaces [7], biochemical evidence indicates that TFPI inhibition is not instantaneous and fails to block all functions of nascent product FXa [11].

This conclusion is supported by studies with a protease domain mutant of FVIIa (FVIIa E154A). This mutant can convert FX to FXa but is highly defective in releasing the nascent product FXa. Thrombin generation in plasma initiated by this mutant requires the anti-hemophilic FIX and FVIII. Importantly, the nascent FXa generated by the mutant FVIIa complex with TF directly activated FVIII, but not FV [11]. Remarkably, even supraphysiological concentrations of TFPI could not block nascent product FXa mediated FVIII activation, although TF-FVIIa generated FXa was prevented from assembling into the prothrombinase complex (Fig. 3). Consistent with these results, studies in reconstituted blood showed that the mutant was almost as effective as wild-type FVIIa to initiate FVIII-dependent platelet and fibrin deposition under flow. Thus, nascent product FXa may have a
distinct role in triggering the FVIII-FIX pathway involved in hemostasis in contrast to the functions of FXa in the prothrombinase and thrombosis.

Nascent FXa is also critically involved in cell signaling processes. As discussed above, high affinity for FVIIa characterizes TF which efficiently activates FX. Whereas the TF-FVIIa complex at high concentrations of FVIIa can directly activate PAR2 and supports integrin-dependent endosomal signaling [7, 12] (Fig. 2), low concentrations of FVIIa elicit cell signaling only when FX is present [13]. Signaling of the nascent product FXa is therefore integrated in cell surface TF-initiated coagulation. TF-FVIIa-Xa tertiary complex signaling in endothelial, smooth muscle and cancer cells also requires the endothelial cell protein C receptor (EPCR) (Fig. 3). EPCR binds the Gla-domains of protein C (PC), FVII and FX, but TF-FVIIa-FXa signaling did not require Gla-domain interactions of FVIIa with EPCR [14]. Thus, FXa can recruit additional receptors, in this case EPCR, to modulate the signaling functions of TF. Remarkably, although EPCR mediates endothelial cell protection in inflammation through PAR1 signaling, EPCR recruited to the TF-FVIIa-FXa complex alters the lipopolysaccharide (LPS) response of dendritic cells through PAR2 signaling [15]. In the context of toll like receptor signaling, nascent product FXa engaging TF-FVIIa as well as EPCR is crucial for the expression of type I interferon regulated genes that participate in diverse host defense and autoimmune signaling pathways [6].

The innate immune signaling role of nascent FXa in the TF coagulation initiation complex is surprisingly regulated by the anticoagulant PC pathway. The thrombin-thrombomodulin complex activates PC in an EPCR-dependent manner on endothelial cells. Activated PC typically suppresses coagulation by inactivating the plasma coagulation cofactor VIIIa dependent on non-activated FV and anticoagulant protein S. This pathway is known to be defective in FV Leiden patients which present with the clinical diagnosis of PC resistance. The complex of FV, protein S, and activated PC also suppresses TF-FXa-PAR2 signaling in the context of the endotoxin-induced upregulation of interferon-regulated genes. Because FXa engages EPCR in this signaling complex, the anticoagulant pathway presumably exerts the regulatory function by competition of activated PC with FXa ligand occupancy of EPCR [16]. These experiments emphasize that pro- and anticoagulant pathways are integrated into innate immune responses to microbial or endogenous danger signals.

### Extrahepatic synthesis of FXa as a regulator of the immune system

PARs are sensors for proteolytic activity and PAR activation by coagulation proteases serves as an injury signal for immune cells circulating in blood or lymphatics. Several lines of evidence point to important functions of coagulation proteases activating PARs in extravascular locations (Fig. 3). Although vascular leakage in the context of inflammation may allow coagulation proteases to exit the blood stream, cells in tissue micromilieus can synthesize certain coagulation proteases for regulatory functions through PARs. In the bone marrow niche, FXa can be derived from megakaryocytes and form the prothrombinase to generate extravascular thrombin. The balance between thrombin and the anticoagulant activated PC controls hematopoietic stem and progenitor cell (HSPC) mobilization and quiescence through PAR1 signaling [17]. Being at the apex of the hematopoietic lineages, HSPC differentiation and responses to infection and injury are thereby directly controlled by the coagulation cascade.

In addition to the extrinsic coagulation cofactor and receptor TF, the plasmatic factor V is also synthesized by macrophages, enabling rapid thrombin generation in the peritoneal cavity following infection and in other tissue milieus during thrombo-inflammatory processes [18]. Tissue resident macrophages and tumor-associated macrophages (TAM) also synthesize FVII and FX [19], indicating that initiation of coagulation by TF can lead to the formation of a functional FVa-FXa prothrombinase solely by cell autonomous coagulation factor synthesis. Because TAM support angiogenesis, metastasis and immune evasion, it became a pertinent question whether cell autonomous synthesis of coagulation factors alters macrophage phenotypes in cancer and potentially other diseases.

Studies were conducted in immune competent mice with syngeneic tumor models which allowed for the analysis of adaptive immunity and evaluation of cytotoxic tumor cell killing. Prior clinical trials in cancer patients showed only marginal therapeutic benefits of low molecular weight heparin (LMWH) on tumor growth and cancer progression. We compared the efficacy of LMWH with the FXa inhibitor rivaroxaban in various tumor models [19] and found that both anticoagulants were highly efficacious in preventing spontaneous metastasis, a process that requires intravascular thrombin and platelet activation. However, only rivaroxaban, but not LMWH suppressed tumor growth, indicating that the tissue penetration of small oral FXa inhibitors targeted a crucial extravascular function of FXa. Indeed, we detected the expression of FX along with FVII, but not other coagulation factors in monocytes and macrophages within the tumor microenvironment [19, 20].

---

*Springer*
Because deletion of PAR2 in monocytes and macrophages impaired tumor growth, we first evaluated the role of FXa signaling by generating a PAR2 mutant mouse model in which FXa can no longer cleave PAR2. In these mice, various syngeneic tumor models grew slower and tumor eradicating cytotoxic lymphocytes were enriched in the tumor stroma [19]. In addition, genetic deletion of FXa from macrophages produced a similar reduction in tumor growth along with improved anti-tumor immune responses, but rivaroxaban treatment had no additional effect in mice with macrophage FXa deficiency. Thus, in immune competent mice we uncovered novel immune suppressive roles for FXa activating PAR2 that were not seen in previous studies with immune deficient mice.

In addition, when isolated macrophages were stimulated with tumor cell supernatant, we found that the resulting immune-evasive macrophage polarization was prevented by macrophage deletion of FXa, rendering PAR2 insensitive to FXa cleavage, or by addition of the direct FXa inhibitor rivaroxaban. We also saw a similar reprogramming of macrophages in the tumor stroma under these experimental condition, demonstrating that cell autonomous FXa-PAR2 signaling determines TAM phenotypes and that this signaling pathway can be therapeutically targeted by tissue-penetrating oral FXa inhibitors [19].

Concluding remarks

The definition of FXa as the central enzyme in the common plasmatic coagulation pathway by the work of Haskell Milstone has since then evolved to an understanding of FXa function in cellular signaling processes that crucially regulate immunity. Serine proteases are essential components in the activation of the innate immune defense toll pathway in drosophila. FXa generated and associated with TF-FVIIa appears to perpetuate this central function of antimicrobial host defense by cleaving PAR2 in vertebrates. The regulation of FX activation and its shutdown by inhibitory pathways thus centrally affect many cellular functions beyond the clotting reactions studied extensively in the last century.

Acknowledgements The work described in this review was supported by Grants from the National Institutes of Health, the Alexander von Humboldt Foundation of Germany, the Federal Ministry of Education and Research Germany (BMBF 01EO1003 and 01EO1503), the German Research Foundation (DFG SFB 1292, TR156), and the German Center for Cardiovascular Research (DZHK).

Funding Open Access funding enabled and organized by Projekt DEAL.

Declarations

Conflict of interest Consultancy Iconic Therapeutics, ARCA biopharma, and ownership interest MERU Vasimmune.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Ruf W, Dickinson CD (1998) Allosteric regulation of the cofactor-dependent serine protease coagulation factor VIIa. Trends Cardiovasc Med 8:350–356
2. Norledge B, Petrovan RJ, Ruf W, Olson A (2003) The tissue factor/factor VIIa/factor Xa complex: a model built by docking and site-directed mutagenesis. Proteins 53:640–648
3. Ruf W, Miles DJ, Rehemtulla A, Edgington TS (1992) Tissue factor residues 157–167 are required for efficient proteolytic activation of factor X and factor VII. J Biol Chem 267:22206–22210
4. Langer F, Ruf W (2014) Synergies of phosphatidylserine and protein disulfide isomerase in tissue factor activation. Thromb Haemost 111:590–597
5. Rothmeier AS, Marchese P, Langer F, Kamikubo Y, Schaffner F, Cantor J, Ginsberg MH, Ruggeri ZM, Ruf W (2017) Tissue factor prothrombotic activity is regulated by Integrin-arf6 trafficking. Arterioscler Thromb Vasc Biol 37:1323–1331. https://doi.org/10.1161/ATVBAHA.117.309315
6. Muller-Callega N, Hollerbach A, Royce J, Ritter S, Pedrosa D, Madhusudhan T, Teifel S, Meineck M, Hauser F, Canisius A, Nguyen TS, Braun J, Bruns K, Etzold A, Zechner U, Strand S, Radsak M, Strand D, Gu JM, Weinmann-Menke J, Esmon CT, Teyton L, Lackner KJ, Ruf W (2021) Lipid presentation by the protein C receptor links coagulation with autoimmunity. Science. https://doi.org/10.1126/science.abc0956
7. Muller-Callega N, Hollerbach A, Ritter S, Pedrosa DG, Strand D, Graf C, Reinhardt C, Strand S, Poncelet P, Griffin JH, Lackner KJ, Ruf W (2019) Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis. Blood 134:1119–1131. https://doi.org/10.1182/blood.201901530
8. Subramaniam S, Jurk K, Hobohm L, Jackel S, Saffarzadeh M, Schwierzzek K, Wenzel P, Langer F, Reinhardt C, Ruf W (2017) Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development. Blood 129:2291–2302. https://doi.org/10.1182/blood-2016-11-749879
9. Yang X, Cheng X, Tang Y, Qiu X, Wang Y, Kang H, Wu J, Wang Z, Liu Y, Chen F, Xiao X, Mackman N, Billiar TR, Han J, Lu B (2019) Bacterial endotoxin activates the coagulation cascade through gasdermin D-dependent phosphatidylserine exposure. Immunity 51(983–96):e6. https://doi.org/10.1016/j.immuni.2019.11.005
10. Ahamed J, Belting M, Ruf W (2005) Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1. Blood 105:2384–2391
11. Kamikubo Y, Mendolucchio GL, Zampolli A, Marchese P, Rothmeier AS, Orje JN, Gale AJ, Krishnaswamy S, Gruber A, Ostergaard H, Petersen LC, Ruf W, Ruggeri ZM (2017) Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex. Blood 130:1661–1670. https://doi.org/10.1182/blood-2017-02-767079
12. Rothmeier AS, Liu E, Chakrabarty S, Disse J, Mueller BM, Ostergaard H, Ruf W (2018) Identification of the integrin-binding site on coagulation factor VIIa required for proangiogenic PAR2 signaling. Blood 131:674–685. https://doi.org/10.1182/blood-2017-02-768218
13. Zelaya H, Rothmeier AS, Ruf W (2018) Tissue factor at the crossroad of coagulation and cell signaling. J Thromb Haemost 16:1941–1952. https://doi.org/10.1111/jth.14246
14. Disse J, Petersen HH, Larsen KS, Persson E, Esmon N, Esmon CT, Teyton L, Petersen LC, Ruf W (2011) The endothelial protein C receptor supports tissue factor ternary coagulation initiation complex signaling through protease-activated receptors. J Biol Chem 286:5756–5767
15. Liang HP, Kerschen EJ, Hernandez I, Basu S, Zogg M, Botros F, Jia S, Hessner MJ, Griffin HJ, Ruf W, Weiler H (2015) EPCR-dependent PAR2 activation by the blood coagulation initiation complex regulates LPS-triggered interferon responses in mice. Blood 125:2845–2854
16. Liang HP, Kerschen EJ, Basu S, Hernandez I, Zogg M, Jia S, Hessner MJ, Toso R, Rezaie AR, Fernandez JA, Camire RM, Ruf W, Griffin HJ, Weiler H (2015) Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice. Blood 126:2415–2423
17. Nguyen TS, Lapidot T, Ruf W (2018) Extravascular coagulation in hematopoietic stem and progenitor cell regulation. Blood 132:123–131. https://doi.org/10.1182/blood-2017-12-768986
18. Zhang N, Czepielewski RS, Jarjour NN, Erlich EC, Esaulova E, Saunders BT, Grover SP, Cleuren AC, Broze GJ, Edelson BT, Mackman N, Zinselmeyer BH, Randolph GJ (2019) Expression of factor V by resident macrophages boosts host defense in the peritoneal cavity. J Exp Med 216:1291–1300. https://doi.org/10.1084/jem.20182024
19. Graf C, Wilgenbus P, Pagel S, Pott J, Marini F, Reyda S, Kitano M, Macher-Goppinger S, Weiler H, Ruf W (2019) Myeloid cells-synthesized coagulation factor X dampens antitumor immunity. Sci Immunol. https://doi.org/10.1126/sciimmunol.aaw8405
20. Schaffner F, Yokota N, Carneiro-Lobo TC, Kitano M, Schaffer M, Anderson GM, Mueller BM, Esmon CT, Ruf W (2013) Endothelial protein C receptor function in murine and human breast cancer development. PLoS ONE 8:e61071

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.